Back to News
Market Impact: 0.3
Orano Med Inaugurates ATLab Valenciennes, Europe’s First Industrial Facility Dedicated to the Production of Lead-212-Based Targeted Alpha Therapies
Source: Business Wire
Healthcare & BiotechTechnology & InnovationInfrastructure & Defense
Orano Med inaugurated Europe’s first industrial-scale pharmaceutical facility dedicated to producing lead-212-based radioligand therapies in Valenciennes, France. The facility expands manufacturing infrastructure for targeted radiopharmaceutical cancer treatments and could support commercialization and supply capacity for lead-212 therapies.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.45
More News
- New aircraft carrier, 10,000 US troops: Is the Iran war about to escalate?
- U.S. to send third carrier group to Mideast as Trump warns of new Iran strikes
- US Adds Carrier and 10,000 Troops to Mideast
- FAA says Boeing 737 Max software glitch not a flight-safety issue
- Your health insurance premiums may take a big jump in 2027 — here's why
- Anthropic to invest $100 million to train AI engineer talent